Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

APPY 0.453 -0.001 (-0.33%)
price chart
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced by ...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of purchasers of the securities of Venaxis, Inc. (�Venaxis� or the �Company�) (NASDAQ:APPY ...
Venaxis, Inc. to Present at Biotech Showcase� 2015
6, 2015 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, and young ...
Related articles »  
Robbins Arroyo LLP: Venaxis, Inc. (APPY) Misled Shareholders According to a ...
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Venaxis, Inc. APPY, +0.74% has filed a federal securities fraud class action complaint in the U.S.
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces ...
NEW YORK, Jan. 29, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Venaxis, Inc. ("Venaxis" or the "Company") (NasdaqCM: APPY -News).
Venaxis, Inc. Price Target Update
Venaxis, Inc. (NASDAQ:APPY): 1 Analyst have given the stock of Venaxis, Inc. (NASDAQ:APPY) a near short term price target of $0.5.
Volatile Stocks: Venaxis Inc , Lexington Realty Trust , Zimmer Holdings Inc  Winston View
NASDAQ:APPY Investor filed Lawsuit over alleged Securities Laws Violations ...  Empowered News
INVESTOR ALERT: Investigation on Behalf of Investors of Venaxis, Inc ...
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. (�Venaxis� or the �Company�) (NASDAQ:APPY) concerning possible violations of federal securities ...
INVESTOR ALERT: Investigation of Venaxis, Inc. Announced by Glancy Binkow ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Venaxis, Inc. (�Venaxis� or the �Company�) (NASDAQ:APPY) concerning possible violations of federal securities ...
Venaxis, Inc. (APPY) Presents APPY1 Test Data at ACEP14
Venaxis, Inc. (NASDAQ: APPY) announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ...  PR Newswire (press release)
Related articles »  
Venaxis Inc (APPY) Stock Crashes On FDA's �Not Substantially Equivalent ...
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Morning Market Losers  Benzinga
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
First Call Rating Update on Venaxis, Inc.
Venaxis, Inc. (NASDAQ:APPY) was among the losers of the day with the shares closing down 0.0028 points or 0.55%. The pessimistic mood was evident in the counter which never went considerably beyond the opening level of $0.5384.